Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients.
Adult
Aged
Aged, 80 and over
Female
Follow-Up Studies
Humans
Immunologic Factors
/ therapeutic use
Leukemia, Plasma Cell
/ etiology
Male
Middle Aged
Multiple Myeloma
/ complications
Proteasome Inhibitors
/ therapeutic use
Retrospective Studies
Salvage Therapy
/ methods
Stem Cell Transplantation
Survival Analysis
Transplantation, Autologous
Treatment Outcome
Autologous stem cell transplantation
proteasome inhibitors
secondary plasma cell leukemia
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
pubmed:
3
7
2018
medline:
1
1
2020
entrez:
3
7
2018
Statut:
ppublish
Résumé
This multicenter retrospective study included 101 patients (median age 62 years) with secondary plasma cell leukemia (sPCL). The median time from initial multiple myeloma diagnosis to sPCL was 31 months. Fifty-five out of 72 patients (75%) who received any therapy were treated with immunomodulators (IMiDs) and/or proteasome inhibitors (PIs), and 14/72 (19%) underwent salvage autologous stem cell transplantation (ASCT). The overall response rate in patients who received ASCT or PI (either alone or in combination) was higher than in those who did not (93% vs. 36% and 60% vs. 30%, respectively). The median overall survival (OS) in patients who received therapy was 4.2 months (95% CI: 1.3; 8.0) with a 1-year OS of 19%. Platelet count ≤100 × 10
Identifiants
pubmed: 29965787
doi: 10.1080/10428194.2018.1473574
doi:
Substances chimiques
Immunologic Factors
0
Proteasome Inhibitors
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM